|Bid||108.00 x 382500|
|Ask||0.00 x 252100|
|Day's range||111.70 - 114.90|
|52-week range||109.50 - 166.97|
|PE ratio (TTM)||-16.34|
|Dividend & yield||N/A (N/A)|
|1y target est||181.88|
Are these two companies cheap enough to merit purchase right now?
GlaxoSmithKline (Other OTC: GLAXF - news) is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) said on Thursday the Food and Drug Administration (FDA) had decided not to approve its version of the inhaled treatment for asthma and chronic lung disease at this time, due to "major" issues with the application. Hikma and its partner Vectura are in a race with Mylan to launch the first U.S. generic copy of Advair that can be substituted for the original product in pharmacies.
** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9% ** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair ...